首页 > 市场调查报告书 > 製药

孤儿药

市场调查报告书

商品编码

1378576

化疗引起的血小板减少性疾病治疗药物市场：依药物类别、给药途径、通路和地区

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年09月29日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球化疗引起的血小板血小板减少性疾病治疗市场估计为15.313亿美元，预计在预测期内（2023-2030年）年复合成长率为5%。

报告范围		报告详情
基准年	2022年	2023年市场规模	15.313 亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	5.00%	2030年市场规模预测	21.546 亿美元

图 1. 2023 年化疗引起的血小板血小板减少性疾病药物的全球市场占有率(%)（按药物类别）

化疗引起的血小板减少性疾病(CIT) 是一种常见病理，与癌症患者化疗给药减少、治疗中断、出血併发症和不良结局有关。目前，CIT的预防和管理尚无明确的指引。为了应对这一挑战，血小板生成素 (TPO) 替代疗法已被开发并采用作为透过刺激巨核细胞生成和促进血小板生成来解决 CIT 的方法。儘管血小板输注是治疗癌症患者严重CIT 的主要方法，但仍有相当大的需求未被满足。这些包括持续高出血率以及需要调整剂量或延迟给药。

市场动态

用于治疗化疗引起的血小板血小板减少性疾病的研发线产品的增加预计将推动市场成长。例如，Nplate（Amgen）是一种血小板生成素受体促效剂（TPO-RA）。用于治疗化疗引起的血小板减少性疾病(CIT) 的 3 期试验正在进行中。处于阶段临床试验中并有可能获得监管部门核准的主要候选药物数量不断增加，这为药品製造商将治疗 CIT 的新药推向市场提供了重要机会。我是。例如，2020年10月19日，血液和血液疾病研究所医院启动了一项单臂试验，以评估艾曲波帕治疗化疗引起的血小板血小板减少性疾病的安全性和有效性。该研究正处于第二阶段，预计将于 2023 年 12 月完成。

本次调查的主要特点

本报告对全球化疗引起的化疗血小板减少性疾病治疗市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和復合年度（年复合成长率）。
它揭示了各个细分市场的潜在收益成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、业绩和策略等参数对全球化疗引起的化疗血小板减少性疾病治疗市场的主要参与者进行了分析。
本研究涵盖的主要企业包括安进公司、诺华公司、辉瑞公司、瑞典Orphan Biovitrum AB、江苏恆瑞医药有限公司、梯瓦製药工业有限公司和Mylan NV。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
全球化疗引起的血小板血小板减少性疾病治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球化疗引起的血小板血小板减少性疾病治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 1,531.3 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.00%	2030 Value Projection:	US$ 2,154.6 Mn

Chemotherapy-induced Thrombocytopenia (CIT) is a prevalent medical condition associated with reduced chemotherapy doses, treatment interruptions, bleeding complications, and unfavorable outcomes in cancer patients. Currently, there exists a lack of well-defined guidelines for the prevention and management of CIT. In response to this challenge, thrombopoietin (TPO) replacement therapy has been developed and employed as an approach to address CIT by stimulating the production of megakaryocytes and expediting platelet generation. Despite platelet transfusions being the primary approach to managing severe CIT in cancer patients, there remain substantial unmet needs. These include persistently high rates of bleeding events and the necessity for adjustments or delays in anticancer therapy dosages.

Market Dynamics

The increasing number of pipeline products for the treatment of chemotherapy-induced thrombocytopenia is expected to drive the market growth. For instance, Nplate (Amgen Inc.) is a thrombopoietin receptor agonist (TPO-RA). It is being investigated in phase 3 for the treatment of chemotherapy-induced thrombocytopenia (CIT).

Thus, rising number of lead candidates in late phase clinical trial having the potential to gain regulatory approval is providing robust opportunities for pharmaceutical manufacturers to launch novel drugs for the treatment of CIT.

For instance, on October 19, 2020, Institute of Hematology & Blood Diseases Hospital initiated the single-arm study to evaluate the safety and efficacy of eltrombopag to treat chemotherapy-induced thrombocytopenia. The study is under Phase II trial and is expected to complete by December 2023.

Key features of the study:

This report provides an in-depth analysis of the global chemotherapy-induced thrombocytopenia therapeutics market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chemotherapy-induced thrombocytopenia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chemotherapy-induced thrombocytopenia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chemotherapy-induced thrombocytopenia therapeutics market

Global Chemotherapy-induced Thrombocytopenia Therapeutics Market Detailed Segmentation:

By Drug Class:
- Thrombopoietin Receptor Agonists
- Thrombopoietic Agents
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Amgen, Inc.
- Novartis AG
- Pfizer Inc.
- Swedish Orphan Biovitrum AB
- Jiangsu HengRui Medicine Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on the Healthcare Sector
Total Impact of COVID-19 on the Global Chemotherapy-induced Thrombocytopenia Therapeutics Market
Supply and Demand Analysis

5. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Thrombopoietin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

6. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

7. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends

8. Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- Amgen, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Swedish Orphan Biovitrum AB
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Jiangsu HengRui Medicine Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Mylan N.V.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

化疗引起的血小板减少性疾病治疗药物市场：依药物类别、给药途径、通路和地区

Chemotherapy Induced Thrombocytopenia Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

市场动态

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球化疗-血小板减少性疾病治疗药物市场-新型冠状病毒感染疾病（COVID-19）的影响分析

第5章全球化疗引起的血小板减少性疾病治疗药物市场，依药物类别，2018-2030

第6章全球化疗引起的血小板减少性疾病治疗药物市场，依给药途径，2018-2030

第7章全球化疗引起的血小板减少性疾病治疗药物市场，依配销通路，2018-2030

第8章2018-2030年全球化疗引起的血小板减少性疾病治疗药物市场（按地区）

第9章竞争形势

第10章章